{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:27:55Z","timestamp":1787239675791,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Teriparatide was the first anabolic agent recommended for the treatment of osteoporosis. Long-term real-world, controlled studies are not available. The purpose was to evaluate the long-term effects of treatment with teriparatide on fractures and Health Related Quality of Life in subjects with established osteoporosis in comparison with placebo treated patients with osteoporosis and the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A 10-year follow-up was performed after a prospective, open-labelled study with teriparatide 20\u2009\u03bcg given subcutaneously daily for a mean of 18\u2009months (range 14\u201324\u2009months) in 40 women, mean age 69\u2009years, with osteoporosis and vertebral compression. Placebo treated women,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925, mean age 60\u2009years, from a randomized, double-blind, placebo-controlled growth hormone trial with daily subcutaneous injections for 18\u2009months, with osteoporosis were used as controls. Dual energy x-ray absorptiometry and questionnaires were performed at start, after 18\u2009months, after 36\u2009months and after 10\u2009years. Women,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009233, of similar age from a random population sample, also served as controls and were followed in parallel. All fractures were X-ray verified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fractures decreased from 100 to 35% in the teriparatide treated patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) to similar levels as in the population sample, 25 to 28% at start and after 10\u2009years, respectively. Bone mineral density increased on teriparatide but returned to levels at treatment start after 10\u2009years. Health Related Quality of Life was lower in the teriparatide group than in the population (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) before and, after treatment and at 10\u2009years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anabolic hormonal treatment with teriparatide reduced fracture prevalence to similar levels as in the general population at 10\u2009years\u2019 follow-up. Health Related Quality of Life was low in osteoporosis and unaffected by bone specific treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12891-022-05987-2","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:19:22Z","timestamp":1669295962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Teriparatide treatment in severe osteoporosis \u2013 a controlled 10-year follow-up study"],"prefix":"10.1186","volume":"23","author":[{"given":"Georgios","family":"Kontogeorgos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Krantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Trimpou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Laine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Landin-Wilhelmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"issue":"1","key":"5987_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11657-021-00969-8","volume":"17","author":"C Willers","year":"2022","unstructured":"Willers C, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, et al. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022;17(1):23.","journal-title":"Arch Osteoporos"},{"issue":"24 Suppl","key":"5987_CR2","doi-asserted-by":"publisher","first-page":"12s","DOI":"10.1097\/00007632-199712151-00003","volume":"22","author":"DL Glaser","year":"1997","unstructured":"Glaser DL, Kaplan FS. Osteoporosis. Definition and clinical presentation. Spine. 1997;22(24 Suppl):12s\u20136s.","journal-title":"Spine"},{"issue":"19","key":"5987_CR3","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434\u201341.","journal-title":"N Engl J Med"},{"issue":"3","key":"5987_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1359\/jbmr.2003.18.3.393","volume":"18","author":"K Landin-Wilhelmsen","year":"2003","unstructured":"Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J Bone Miner Res. 2003;18(3):393\u2013405.","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"5987_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American association of clinical endocrinologists\/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26(Suppl 1):1\u201346.","journal-title":"Endocr Pract"},{"issue":"3","key":"5987_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30(3):312\u201321.","journal-title":"Toxicol Pathol"},{"issue":"4","key":"5987_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/01926230490462138","volume":"32","author":"JL Vahle","year":"2004","unstructured":"Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004;32(4):426\u201338.","journal-title":"Toxicol Pathol"},{"issue":"2","key":"5987_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/jbmr.4188","volume":"36","author":"A Gilsenan","year":"2021","unstructured":"Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US Postmarketing surveillance study. J Bone Miner Res. 2021;36(2):244\u201351.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"5987_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00198-003-1547-4","volume":"15","author":"W Cockerill","year":"2004","unstructured":"Cockerill W, Lunt M, Silman AJ, Cooper C, Lips P, Bhalla AK, et al. Health-related quality of life and radiographic vertebral fracture. Osteoporos Int. 2004;15(2):113\u20139.","journal-title":"Osteoporos Int"},{"issue":"4","key":"5987_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00198-007-0488-8","volume":"19","author":"C Cooper","year":"2008","unstructured":"Cooper C, Jakob F, Chinn C, Martin-Mola E, Fardellone P, Adami S, et al. Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the observational study of severe osteoporosis (OSSO). Osteoporos Int. 2008;19(4):493\u2013501.","journal-title":"Osteoporos Int"},{"issue":"4","key":"5987_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00223-018-0437-x","volume":"103","author":"N Napoli","year":"2018","unstructured":"Napoli N, Langdahl BL, Ljunggren \u00d6, Lespessailles E, Kapetanos G, Kocjan T, et al. Effects of Teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European extended Forsteo\u00ae observational study (ExFOS). Calcif Tissue Int. 2018;103(4):359\u201371.","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"5987_CR12","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1185\/03007995.2014.907561","volume":"30","author":"O Ljunggren","year":"2014","unstructured":"Ljunggren O, Benhamou CL, Dekker J, Kapetanos G, Kocjan T, Langdahl BL, et al. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS). Curr Med Res Opin. 2014;30(8):1607\u201316.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"5987_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00223-016-0143-5","volume":"99","author":"BL Langdahl","year":"2016","unstructured":"Langdahl BL, Ljunggren O, Benhamou CL, Marin F, Kapetanos G, Kocjan T, et al. Fracture rate, quality of life and Back pain in patients with osteoporosis treated with Teriparatide: 24-month results from the extended Forsteo observational study (ExFOS). Calcif Tissue Int. 2016;99(3):259\u201371.","journal-title":"Calcif Tissue Int"},{"issue":"8848","key":"5987_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/0140-6736(93)90571-W","volume":"341","author":"R Lindsay","year":"1993","unstructured":"Lindsay R. Prevention and treatment of osteoporosis. Lancet (London, England). 1993;341(8848):801\u20135.","journal-title":"Lancet (London, England)"},{"issue":"3","key":"5987_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1046\/j.1365-2796.1997.00163.x","volume":"242","author":"L Wilhelmsen","year":"1997","unstructured":"Wilhelmsen L, Johansson S, Rosengren A, Wallin I, Dotevall A, Lappas G. Risk factors for cardiovascular disease during the period 1985-1995 in G\u00f6teborg, Sweden. The GOT-MONICA project. J Intern Med. 1997;242(3):199\u2013211.","journal-title":"J Intern Med"},{"issue":"5","key":"5987_CR16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1530\/EJE-11-0808","volume":"166","author":"P Trimpou","year":"2012","unstructured":"Trimpou P, Lindahl A, Lindstedt G, Oler\u00f6d G, Wilhelmsen L, Landin-Wilhelmsen K. Secular trends in sex hormones and fractures in men and women. Eur J Endocrinol. 2012;166(5):887\u201395.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"5987_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy (Amsterdam, Netherlands). 1996;37(1):53\u201372.","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"issue":"4","key":"5987_CR18","doi-asserted-by":"publisher","first-page":"e024454","DOI":"10.1136\/bmjopen-2018-024454","volume":"9","author":"E Krantz","year":"2019","unstructured":"Krantz E, Wide U, Trimpou P, Bryman I, Landin-Wilhelmsen K. Comparison between different instruments for measuring health-related quality of life in a population sample, the WHO MONICA project, Gothenburg, Sweden: an observational, cross-sectional study. BMJ Open. 2019;9(4):e024454.","journal-title":"BMJ Open"},{"issue":"1","key":"5987_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/jbmr.5650060106","volume":"6","author":"R Smith-Bindman","year":"1991","unstructured":"Smith-Bindman R, Cummings SR, Steiger P, Genant HK. A comparison of morphometric definitions of vertebral fracture. J Bone Miner Res. 1991;6(1):25\u201334.","journal-title":"J Bone Miner Res"},{"key":"5987_CR20","doi-asserted-by":"crossref","unstructured":"Krantz E, Trimpou P, Landin-Wilhelmsen K. Effect of growth hormone treatment on fractures and quality of life in postmenopausal osteoporosis: a10-year follow-up study. J. Clin Endocrinol Metab. 2015;100(9):3251-9.","DOI":"10.1210\/jc.2015-1757"},{"issue":"6","key":"5987_CR21","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s00223-009-9299-6","volume":"85","author":"BL Langdahl","year":"2009","unstructured":"Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo observational study (EFOS). Calcif Tissue Int. 2009;85(6):484\u201393.","journal-title":"Calcif Tissue Int"},{"key":"5987_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/1471-2474-14-251","volume":"14","author":"O Ljunggren","year":"2013","unstructured":"Ljunggren O, Barrett A, Stoykov I, Langdahl BL, Lems WF, Walsh JB, et al. Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo observational study. BMC Musculoskelet Disord. 2013;14:251.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"5987_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9\u201317.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"5987_CR24","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00198-013-2284-y","volume":"24","author":"S Silverman","year":"2013","unstructured":"Silverman S, Miller P, Sebba A, Weitz M, Wan X, Alam J, et al. The direct assessment of nonvertebral fractures in community experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int. 2013;24(8):2309\u201317.","journal-title":"Osteoporos Int"},{"key":"5987_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.bone.2014.07.014","volume":"67","author":"EF Eriksen","year":"2014","unstructured":"Eriksen EF, Keaveny TM, Gallagher ER, Krege JH. Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone. 2014;67:246\u201356.","journal-title":"Bone."},{"issue":"1","key":"5987_CR26","doi-asserted-by":"publisher","first-page":"e10551","DOI":"10.1002\/jbm4.10551","volume":"6","author":"A Dotevall","year":"2022","unstructured":"Dotevall A, Krantz E, Barren\u00e4s ML, Landin-Wilhelmsen K. Hearing and balance exceed initial bone mineral density in predicting incident fractures: a 25-year prospective observational study in menopausal women with osteoporosis. JBMR Plus. 2022;6(1):e10551.","journal-title":"JBMR Plus"},{"issue":"7","key":"5987_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s001980070075","volume":"11","author":"JA Cauley","year":"2000","unstructured":"Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11(7):556\u201361.","journal-title":"Osteoporos Int"},{"issue":"5","key":"5987_CR28","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595\u2013622.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"5987_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3\u201344.","journal-title":"Osteoporos Int"},{"issue":"2","key":"5987_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1046\/j.1365-2796.2000.00642.x","volume":"247","author":"K Landin-Wilhelmsen","year":"2000","unstructured":"Landin-Wilhelmsen K, Johansson S, Rosengren A, Dotevall A, Lappas G, Bengtsson BA, et al. Calcaneal ultrasound measurements are determined by age and physical activity. Studies in two Swedish random population samples. J Intern Med. 2000;247(2):269\u201378.","journal-title":"J Intern Med"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-022-05987-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-022-05987-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-022-05987-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:22:51Z","timestamp":1669296171000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-022-05987-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5987"],"URL":"https:\/\/doi.org\/10.1186\/s12891-022-05987-2","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"30 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the National and Regional Ethics Committee in Sweden and the University of Gothenburg. For the teriparatide -study: D-number 2004: M-004 approved in 2004, D-number 2006: 098 approved in 2006 and D-number 1142\u201318\/2019\u201300738 approved in 2019; for the growth hormone-study: D-number 386\u201392 approved in 1993, D-number 543\u201300 approved in 2001 and D-number 2019\u201305675 approved in 2020; and for the WHO MONICA project Gothenburg: D-number 244\u201394 approved in 1994, D-number 088\u201306 approved in 2006 and D-number T282\u201311 approved in 2011. All participants gave their written informed consent. The Declaration of Helsinki was followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests in this section.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1011"}}